CVD Risk with Long-Acting Bronchodilators Fades After One Month

Join our community to access additional content!

CRT Community

$0.00

Register for Meetings

“In The News” & “Cardiovascular Marketplace” Content Access

Listen to Podcasts

Watch On-Demand Content

CardioTube Access

Access to Recorded Live Broadcasts from CRTvirtual Meetings, DMV, & Cath Conference

Access Recorded Interviews

Download PPT Slide Decks

Join Now!
Already have an account? Login Now

CRT Community Premium

$650 Annually

Register for Meetings

“In The News” & “Cardiovascular Marketplace” Content Access

Listen to Podcasts

Watch On-Demand Content

CardioTube Access

Access to Recorded Live Broadcasts from CRTvirtual Meetings, DMV, & Cath Conference

Access Recorded Interviews

Download PPT Slide Decks

Complimentary subscription to electronic version of the CRM Journal

Access to CRT Meeting Registration Discounts

CRT Premium Content, including on-demand videos and presentation downloads

Join Now!
Already have an account? Login Now
News

CVD Risk with Long-Acting Bronchodilators Fades After One Month

Posted: 01/02/2018
Author:
Nicole Lou, Contributing Writer, MedPage Today, January 02, 2018
2018 News Articles

For COPD patients, risk greatest 30 days after starting LAMAs/LABAs

Inhaled long-acting bronchodilators may carry an elevated cardiovascular risk in the first 30 days of use by patients with chronic obstructive pulmonary disease (COPD), but it tapers afterward, according to a randomized study.
1-3 of 2638 results
1 2 3 4 5 Next »

ViV-TAVR has Similar Mortality, Fewer Complications at 2-Years Compared With Redo-SAVR: Retrospective Study

Oct 16, 2024 by
Bailey G. Salimes, CRTonline.org

Valve-in-valve transcatheter aortic valve replacement (ViV-TAVR) is associated with fewer periprocedural cardiovascular complications and similar rates of all-cause mortality, compared with redo-surgical aortic valve replacement (SAVR), a new retrospective analysis shows.

Adipose Tissue Location an Important Factor in the Development of HF in Patients With Obesity: State-of-the-Art Review

Oct 14, 2024 by
Bailey G. Salimes, CRTonline.org

Epicardial adipose tissue (EAT) depots, highly specialized adipose tissue (AT) depots, are an important contributor to the development of heart failure (HF), and show a distinct response to obesity, a new state-of-the-art review shows.

Treating CVD to Improve Brain Health: AHA Scientific Statement on the Heart-Brain Connection

Oct 14, 2024 by
Bailey G. Salimes, CRTonline.org

A scientific statement from the American Heart Association (AHA) shows that addressing cardiovascular health earlier in life can reduce the risk of stroke and prevent earlier onset or progression of later-life cognitive impairment.

1-3 of 2638 results
1 2 3 4 5 Next »

Most Viewed Pages

ViV-TAVR has Similar Mortality, Fewer Complications at 2-Years Compared With Redo-SAVR: Retrospective Study

Adipose Tissue Location an Important Factor in the Development of HF in Patients With Obesity: State-of-the-Art Review

Treating CVD to Improve Brain Health: AHA Scientific Statement on the Heart-Brain Connection

BRIGHT-4 External Confirmation: Mortality, Bleeding Reduced, no Increase in Ischemic Events, in STEMI Patients Receiving Bivalirudin Plus High-Dose Infusion Post-PCI

Fusion Mixed Reality: A Novel Approach to Merge the Physical and Virtual Cath Lab

Explore the Site

Stay Connected

CRT Group Foundation is a not for profit corporation dedicated to providing educational services in the field of cardiology through the website, CRTonline.org and the Cardiovascular Research Technologies (CRT) annual symposium. CRT focuses on the advances and changes in the field of cardiovascular medicine. CRT is designed to provide access to the world’s leading clinicians and the latest research in order to improve practice and treatment outcomes for a variety of health care professionals.

This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies. Review our Privacy Policy for more details

Join our community to access additional content!

CRT Community

CRT Community Premium

News

CVD Risk with Long-Acting Bronchodilators Fades After One Month

For COPD patients, risk greatest 30 days after starting LAMAs/LABAs

ViV-TAVR has Similar Mortality, Fewer Complications at 2-Years Compared With Redo-SAVR: Retrospective Study

Adipose Tissue Location an Important Factor in the Development of HF in Patients With Obesity: State-of-the-Art Review

Treating CVD to Improve Brain Health: AHA Scientific Statement on the Heart-Brain Connection

Most Viewed Pages

Explore the Site

Stay Connected